131
Participants
Start Date
November 20, 2013
Primary Completion Date
October 31, 2017
Study Completion Date
October 31, 2017
BGB-283
"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
Prince of Wales Hospital, Randwick
Chris Obrien Lifehouse, Camperdown
Westmead Hospital, Westmead
North Coast Cancer Institute, Macquarie
Peter Maccallum Cancer Centre, Melbourne
Alfred Cancer Trials, Melbourne
Royal Melbourne Hospital, Parkville
Austin Health, Heidelberg
Box Hill Hospital, Box Hill
Cabrini Hospital Malvern, Malvern
Monash Health, Clayton
Waikato Hospital, Hamilton Waikato
Princess Alexandra Hospital, Brisbane
Tasman Oncology Research Ltd, Southport Gold Coast
Royal Adelaide Hospital, Adelaide
Linear Clinical Research, Nedlands
Wellington Regional Hospital (Ccdhb), Wellington
Christchurch Hospital, Christchurch
Dunedin Hospital, Dunedin
Lead Sponsor
BeiGene
INDUSTRY